:  +1-617-803-9415
  • Our Service

  • Oncology /Immuno-oncology Platform
  • Humanized Model (Human Immune System Reconstitution)
  • Syngeneic Mouse Model
  • PDX Model
  • CDX Model
  • Nude Rat Models
  • Transgenic Humanized Mice Models
  • Human Cancer Cell Panel
  • Ex-Vivo Tumor Tissue Culture
  • Ex-Vivo Tumor Biomarkers Discovery
  • Non-Human Primates Platform
  • Inflammation/Immune Diseases
  • NHP Bone/Orthopedics Models
  • NHP Hematology
  • Immuno-Function Testing Platform
  • Metabolic Diseases
  • Inflammation/Autoimmune Diseases Model
  • Rheumatoid Arthritis
  • Gouty Arthritis
  • Colitis
  • EAE
  • EAN
  • EAU
  • EIU
  • EAC
  • Psoriasis-like Inflammation
  • System Lupus Erythematosus (SLE)
  • Graft-Versus-Host Disease (GvHD)
  • Sepsis
  • Passive Cutaneous Anaphylaxis (PCA)
  • Delayed Type Hypersensitivity (DTH)
  • Air Pouch
  • Anemia of Inflammation
  • Dry Eye Disease
  • General Inflammation
  • Bone/Orthopedics
  • Bone Loss/Osteoporosis
  • Osteoarthritis
  • Bone Repair
  • Bone Safety
  • Cartilage Tissue Repair
  • Ligament/Tendon
  • Osteomyelitis Model
  • Respiratory Diseases Model
  • Lung Fibrosis
  • Asthma
  • Acute Lung Inflammation
  • Allergic Rhinitis
  • Cough
  • Metabolic/Liver/Cardiovascular Diseases Model
  • Liver Fibrosis and Cirrhosis
  • Nonalcoholic Steatohepatitis (NASH)
  • Immune Response Related Hepatitis
  • Diabetes Mellitus (DM)
  • Kidney Fibrosis
  • Heart failure model
  • Medical Devices
  • Cardiovascular
  • Tissue Engineering
  • Wound Healing
  • Surgery Training
  • Histopathology
  • Soft Tissue Histopathology
  • Bone & Implant Histopathology
  • Histomorphometry
  • News

  • Company News
  • Events
  • Cooperation

  • Frontage
  • Tigermed
  • HMT
  • BioVinc
  • Careers

  • Senior Director
  • Director Scientist
  • BD Manager
  • Principal Scientist
  • Contact Us

  • :  +1-617-803-9415
    search
    Cooperation
    Company Profile

    Hangzhou Tigermed Consulting Co., Ltd(stock symbol: 300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.

     

    Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 63 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Canada, Korea, Australia, Japan, Malaysia, Singapore, India and Romania with over 3600 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative Clinical CRO” in China,owning to our involvement of  over 150 innovative drugs.

     

    For more information about Tigermed, please visit http://www.tigermed.net


    Tigermed Coverage

    63offices in China mainland

    12 overseas offices - Hong Kong China, Taiwan China, Korea, Japan, Malaysia, Singapore, India, Australia, Canada, USA, Switzerland, Romania


    PARTNERS